Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827563 · ClinicalTrials.gov registry record
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
A clinical trial, sponsored by University of Chicago.
- Terminated
- Registry status
- 50
- Enrollment target
NCT04827563: Clinical Trial study, sponsored by University of Chicago.
NCT04827563 is a clinical trial that was terminated before completion, run by University of Chicago. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04827563 was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Primary Outcome
The association between baseline endothelial function and dyspnea in myeloma patients treated with carfilzomib. These associations will be assessed by comparing endothelial function within two cohorts: patients with abnormal baseline endothelial function, and patients with normal baseline endothelial function. Baseline endothelial function will be measured using EndoPat, an FDA-approved device used for health tests. Dyspnea rates will be assessed by participant-reported outcomes using the FACIT
Interventions
- OTHER Blood Tests
- DIAGNOSTIC_TEST Echocardiogram
- OTHER Quality of Life Assessment
- DEVICE EndoPAT
- DEVICE Blood Pressure Cuff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-09-08 |
Why NCT04827563 stopped before completion
NCT04827563 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Blood Tests is the first listed.
NCT04827563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04827563 about?
NCT04827563 is a clinical study titled "Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib". This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the hea...
What is the current status of trial NCT04827563?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2021-03-22. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT04827563?
The interventions under investigation include: Blood Tests (OTHER), Echocardiogram (DIAGNOSTIC_TEST), Quality of Life Assessment (OTHER), EndoPAT (DEVICE), Blood Pressure Cuff (DEVICE).
Who is sponsoring clinical trial NCT04827563?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI